ALSYMPCA (ALpharadin In SYMPtomatic Prostate CAncer) Trial Articles

Articles

#AUA14 - Poster: Further characterization of the effects of prior or no prior docetaxel therapy on CRPC patients with bone metastases receiving Ra-223 in the phase 3 ALSYMPCA trial

ORLANDO, FL USA (UroToday.com) - Presented by Neal D. Shore,¹ Nicholas J. Vogelzang,² Peter Hoskin,³ Sten Nilsson,⁴ Robert Coleman,⁵ Christopher Parker,⁶ Mona Wahba,⁷ Karin Staudacher,⁸ and Oliver Sartor⁹ at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Published May 21, 2014
Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned

Published in Everyday Urology - Oncology Insights: Volume 2, Issue 1
Published Date: March 2017

More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases which leads to a significant increase in morbidity and mortality.^1,2 Patients with metastatic prostate cancer and bone involvement have only a 3% five-year survival, whereas the five-year survival of patients without bone metastases is 56%.
Published June 9, 2017